Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.

Journal of experimental & clinical cancer research : CR - 16 Jan 2015

Tecza Karolina, Pamula-Pilat Jolanta, Kolosza Zofia, Radlak Natalia, Grzybowska Ewa

Abstract excerpt

BACKGROUND: Ovarian malignancies are often diagnosed in advanced stage and at the same time resistance to treatment, both intrinsic and developed during treatment, is sometimes observed. These facts underscore the need for new markers of ovarian cancer risk, as well as markers of treatment effectiveness. METHODS: In this study we genotyped 225 ovarian cancer patients, 64 breast and ovarian cancer patients and 348...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Gene Dosage

Share to Mortality

Share to Neoplasm Grading

Share to Ovarian Neoplasms

Share to Paclitaxel

Source

Open in PubMed Open full text

Identifiers

PMID: 25591549
DOI: 10.1186/s13046-015-0124-y
PMCID: PMC4320471

Genes

ABCB1
ATM
BRCA1
PGR
ABCG2
GSTM1
GSTP1
GSTT1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.PMID 25591549Read ↗

Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.Semantic proximity Read ↗

Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.Semantic proximity Read ↗

‘Genetic profiling’ and ovarian cancer therapy (Review)Semantic proximity Read ↗

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patientsSemantic proximity Read ↗

GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.Semantic proximity Read ↗

Genetic variation in progesterone receptor gene and ovarian cancer risk: A case control study.Semantic proximity Read ↗

Polymorphisms of ABCB1, CYP3A4 and CYP3A5 Genes in Ovarian Cancer and Treatment Response in Poles.Semantic proximity Read ↗

Potential prognostic role of somatic mutations in a set of cancer susceptibility genes in ovarian carcinoma: A follow-up multicentric study from Pakistan.Semantic proximity Read ↗

Clinical significance of ABCB1 genotyping in oncology.Semantic proximity Read ↗

Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma.Semantic proximity Read ↗

Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.Semantic proximity Read ↗

Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.